Breaking News

Tuesday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
On The Fly
Fly Intel: After-Hours Movers » 18:38
12/06/22
12/06
18:38
12/06/22
18:38
MDB

MongoDB

$144.73 /

-4 (-2.69%)

, GWRE

Guidewire

$56.67 /

-1.08 (-1.87%)

, CASY

Casey's General Stores

$230.07 /

-0.765 (-0.33%)

, SWBI

Smith & Wesson Brands

$11.80 /

-0.275 (-2.28%)

, SKIL

Skillsoft

$1.93 /

-0.06 (-3.02%)

, ZUO

Zuora

$7.20 /

-0.18 (-2.44%)

, HQY

HealthEquity

$65.82 /

-1.915 (-2.83%)

, PLAY

Dave & Buster's

$36.14 /

-1.115 (-2.99%)

, AVAV

AeroVironment

$85.20 /

-3.92 (-4.40%)

, SFIX

Stitch Fix

$3.66 /

-0.375 (-9.29%)

, TOL

Toll Brothers

$45.82 /

-1.09 (-2.32%)

, NBIX

Neurocrine

$120.26 /

-3.4 (-2.75%)

Check out this evening's…

ShowHide Related Items >><<
ZUO Zuora
$7.20 /

-0.18 (-2.44%)

TOL Toll Brothers
$45.82 /

-1.09 (-2.32%)

SWBI Smith & Wesson Brands
$11.80 /

-0.275 (-2.28%)

SKIL Skillsoft
$1.93 /

-0.06 (-3.02%)

SFIX Stitch Fix
$3.66 /

-0.375 (-9.29%)

PLAY Dave & Buster's
$36.14 /

-1.115 (-2.99%)

NBIX Neurocrine
$120.26 /

-3.4 (-2.75%)

MDB MongoDB
$144.73 /

-4 (-2.69%)

HQY HealthEquity
$65.82 /

-1.915 (-2.83%)

GWRE Guidewire
$56.67 /

-1.08 (-1.87%)

CASY Casey's General Stores
$230.07 /

-0.765 (-0.33%)

AVAV AeroVironment
$85.20 /

-3.92 (-4.40%)

MDB MongoDB
$144.73 /

-4 (-2.69%)

12/05/22 Baird
MongoDB price target lowered to $205 from $330 at Baird
11/29/22 UBS
MongoDB price target lowered to $200 from $390 at UBS
11/21/22 Morgan Stanley
MongoDB downgraded at Morgan Stanley amid challenging spending environment
11/21/22 KeyBanc
MongoDB initiated with an Overweight at KeyBanc
GWRE Guidewire
$56.67 /

-1.08 (-1.87%)

12/01/22 DA Davidson
Guidewire price target lowered to $90 from $96 at DA Davidson
12/01/22 JPMorgan
Guidewire initiated with an Overweight at JPMorgan
09/12/22 Citi
Guidewire price target lowered to $79 from $88 at Citi
09/08/22 Baird
Guidewire price target lowered to $81 from $99 at Baird
CASY Casey's General Stores
$230.07 /

-0.765 (-0.33%)

11/30/22 Wells Fargo
Casey's General Stores price target raised to $260 from $245 at Wells Fargo
11/29/22 Deutsche Bank
Casey's General Stores price target raised to $286 from $269 at Deutsche Bank
09/09/22 Deutsche Bank
Casey's General Stores price target lowered to $269 from $276 at Deutsche Bank
09/09/22 BMO Capital
Casey's General Stores price target raised to $250 from $235 at BMO Capital
SWBI Smith & Wesson Brands
$11.80 /

-0.275 (-2.28%)

09/09/22 Lake Street
Smith & Wesson Brands price target lowered to $22 from $26 at Lake Street
SKIL Skillsoft
$1.93 /

-0.06 (-3.02%)

10/12/22 Citi
Skillsoft price target lowered to $4.50 from $13.50 at Citi
09/08/22 DA Davidson
Skillsoft price target lowered to $3 from $7 at DA Davidson
09/06/22 B. Riley
Skillsoft price target lowered to $6 from $11 at B. Riley
07/26/22 Oppenheimer
Skillsoft assumed with a Perform at Oppenheimer
ZUO Zuora
$7.20 /

-0.18 (-2.44%)

11/28/22 Needham
Needham adds HubSpot to Conviction List, removes Zuora
10/21/22 Goldman Sachs
Zuora initiated with a Neutral at Goldman Sachs
08/25/22 Needham
Zuora price target lowered to $15 from $24 at Needham
08/25/22 Craig-Hallum
Zuora price target lowered to $16 from $22 at Craig-Hallum
HQY HealthEquity
$65.82 /

-1.915 (-2.83%)

12/05/22 RBC Capital
HealthEquity price target raised to $75 from $70 at RBC Capital
11/02/22 Jefferies
HealthEquity price target raised to $90 from $80 at Jefferies
10/21/22 Goldman Sachs
HealthEquity upgraded to Neutral from Sell at Goldman Sachs
10/11/22 BofA
AdaptHealth, HealthEquity, ViaSat added to 'Endeavor List' at BofA
PLAY Dave & Buster's
$36.14 /

-1.115 (-2.99%)

11/08/22 Deutsche Bank
Dave & Buster's upgraded to Buy from Hold at Deutsche Bank
10/05/22 Piper Sandler
Dave & Buster's price target lowered to $34 from $44 at Piper Sandler
09/09/22 Deutsche Bank
Dave & Buster's price target raised to $48 from $37 at Deutsche Bank
09/08/22 Truist
Dave & Buster's price target raised to $62 from $57 at Truist
AVAV AeroVironment
$85.20 /

-3.92 (-4.40%)

11/18/22 Canaccord
AeroVironment price target raised to $105 from $100 at Canaccord
11/10/22 Raymond James
AeroVironment upgraded to Outperform from Market Perform at Raymond James
11/10/22 Raymond James
AeroVironment upgraded to Outperform from Market Perform at Raymond James
09/30/22 RBC Capital
AeroVironment offers best small-cap exposure to Ukraine war, says RBC Capital
SFIX Stitch Fix
$3.66 /

-0.375 (-9.29%)

09/22/22 Barclays
Stitch Fix price target lowered to $5 from $7 at Barclays
09/21/22 Truist
Stitch Fix price target lowered to $6 from $8 at Truist
09/21/22 Evercore ISI
Stitch Fix price target lowered to $7 from $10 at Evercore ISI
09/21/22 MKM Partners
Stitch Fix price target lowered to $5 from $6 at MKM Partners
TOL Toll Brothers
$45.82 /

-1.09 (-2.32%)

11/22/22 JPMorgan
Toll Brothers upgraded to Overweight from Neutral at JPMorgan
10/21/22 Raymond James
Toll Brothers downgraded to Market Perform from Outperform at Raymond James
10/21/22 Raymond James
Toll Brothers downgraded to Market Perform from Outperform at Raymond James
09/19/22 KeyBanc
KeyBanc more bullish on homebuilder names, upgrades five stocks to Overweight
NBIX Neurocrine
$120.26 /

-3.4 (-2.75%)

11/14/22 Evercore ISI
Neurocrine downgraded to In Line from Outperform at Evercore ISI
11/02/22 BMO Capital
Neurocrine price target raised to $101 from $78 at BMO Capital
11/02/22 Wells Fargo
Neurocrine price target raised to $120 from $110 at Wells Fargo
11/02/22 RBC Capital
Neurocrine price target raised to $117 from $101 at RBC Capital
ZUO Zuora
$7.20 /

-0.18 (-2.44%)

TOL Toll Brothers
$45.82 /

-1.09 (-2.32%)

SWBI Smith & Wesson Brands
$11.80 /

-0.275 (-2.28%)

SKIL Skillsoft
$1.93 /

-0.06 (-3.02%)

SFIX Stitch Fix
$3.66 /

-0.375 (-9.29%)

PLAY Dave & Buster's
$36.14 /

-1.115 (-2.99%)

NBIX Neurocrine
$120.26 /

-3.4 (-2.75%)

MDB MongoDB
$144.73 /

-4 (-2.69%)

HQY HealthEquity
$65.82 /

-1.915 (-2.83%)

GWRE Guidewire
$56.67 /

-1.08 (-1.87%)

CASY Casey's General Stores
$230.07 /

-0.765 (-0.33%)

AVAV AeroVironment
$85.20 /

-3.92 (-4.40%)

TOL Toll Brothers
$45.82 /

-1.09 (-2.32%)

SWBI Smith & Wesson Brands
$11.80 /

-0.275 (-2.28%)

SFIX Stitch Fix
$3.66 /

-0.375 (-9.29%)

ZUO Zuora
$7.20 /

-0.18 (-2.44%)

TOL Toll Brothers
$45.82 /

-1.09 (-2.32%)

SWBI Smith & Wesson Brands
$11.80 /

-0.275 (-2.28%)

SKIL Skillsoft
$1.93 /

-0.06 (-3.02%)

SFIX Stitch Fix
$3.66 /

-0.375 (-9.29%)

PLAY Dave & Buster's
$36.14 /

-1.115 (-2.99%)

NBIX Neurocrine
$120.26 /

-3.4 (-2.75%)

MDB MongoDB
$144.73 /

-4 (-2.69%)

HQY HealthEquity
$65.82 /

-1.915 (-2.83%)

GWRE Guidewire
$56.67 /

-1.08 (-1.87%)

AVAV AeroVironment
$85.20 /

-3.92 (-4.40%)

ZUO Zuora
$7.20 /

-0.18 (-2.44%)

TOL Toll Brothers
$45.82 /

-1.09 (-2.32%)

SWBI Smith & Wesson Brands
$11.80 /

-0.275 (-2.28%)

SFIX Stitch Fix
$3.66 /

-0.375 (-9.29%)

PLAY Dave & Buster's
$36.14 /

-1.115 (-2.99%)

MDB MongoDB
$144.73 /

-4 (-2.69%)

Hot Stocks
Neurocrine announces NBI-827104 did not meet its primary endpoint in Phase 2 » 16:02
12/06/22
12/06
16:02
12/06/22
16:02
NBIX

Neurocrine

$120.38 /

-3.28 (-2.65%)

Neurocrine Biosciences…

Neurocrine Biosciences announced that investigational NBI-827104 did not meet its primary endpoint in the Phase 2 STEAMBOAT study evaluating the efficacy, safety, tolerability and pharmacokinetics of NBI-827104 compared to placebo in pediatric patients with epileptic encephalopathy with continuous spike-and-wave during sleep, or EE-CSWS. NBI-827104 was generally well tolerated.

ShowHide Related Items >><<
NBIX Neurocrine
$120.38 /

-3.28 (-2.65%)

NBIX Neurocrine
$120.38 /

-3.28 (-2.65%)

11/14/22 Evercore ISI
Neurocrine downgraded to In Line from Outperform at Evercore ISI
11/02/22 BMO Capital
Neurocrine price target raised to $101 from $78 at BMO Capital
11/02/22 Wells Fargo
Neurocrine price target raised to $120 from $110 at Wells Fargo
11/02/22 RBC Capital
Neurocrine price target raised to $117 from $101 at RBC Capital
NBIX Neurocrine
$120.38 /

-3.28 (-2.65%)

NBIX Neurocrine
$120.38 /

-3.28 (-2.65%)

Over a week ago
Downgrade
Neurocrine downgraded to In Line from Outperform at Evercore ISI » 05:57
11/14/22
11/14
05:57
11/14/22
05:57
NBIX

Neurocrine

$121.38 /

-1.84 (-1.49%)

Evercore ISI analyst Josh…

Evercore ISI analyst Josh Schimmer downgraded Neurocrine Biosciences to In Line from Outperform with a price target of $130, down from $140. Neurocrine shares have outperformed the broader indices, appreciating 50% over the past six months, Schimmer tells investors in a research note. The analyst says "nothing stands out to us as being able to deliver compelling diversification away from Ingrezza" in next year's clinical readouts.

ShowHide Related Items >><<
NBIX Neurocrine
$121.38 /

-1.84 (-1.49%)

NBIX Neurocrine
$121.38 /

-1.84 (-1.49%)

11/02/22 BMO Capital
Neurocrine price target raised to $101 from $78 at BMO Capital
11/02/22 Wells Fargo
Neurocrine price target raised to $120 from $110 at Wells Fargo
11/02/22 RBC Capital
Neurocrine price target raised to $117 from $101 at RBC Capital
11/02/22 Cantor Fitzgerald
Neurocrine price target raised to $132 from $127 at Cantor Fitzgerald
NBIX Neurocrine
$121.38 /

-1.84 (-1.49%)

NBIX Neurocrine
$121.38 /

-1.84 (-1.49%)

Over a month ago
Conference/Events
Jefferies pharma/biopharma analysts hold analyst/industry conference call » 10:36
11/04/22
11/04
10:36
11/04/22
10:36
ARGX

Argenx

$366.40 /

-9.73 (-2.59%)

, BMRN

BioMarin

$83.47 /

-1.38 (-1.63%)

, NBIX

Neurocrine

$122.17 /

-1.95 (-1.57%)

, JAZZ

Jazz Pharmaceuticals

$145.16 /

+0.25 (+0.17%)

, HZNP

Horizon Therapeutics

$73.43 /

+0.53 (+0.73%)

, ARVN

Arvinas

$47.20 /

-1.88 (-3.83%)

, GILD

Gilead

$80.11 /

+0.62 (+0.78%)

, AMGN

Amgen

$266.25 /

+0.39 (+0.15%)

, BIIB

Biogen

$281.18 /

+0.6 (+0.21%)

, MRNA

Moderna

$153.48 /

+5.94 (+4.03%)

Analysts provide an…

Analysts provide an update on Biopharma trading flow, IPO/Secondary flow and mergers and acquisitions flow on an Analyst/Industry conference call to be held on November 4 at 10:30 am. Webcast Link

ShowHide Related Items >><<
NBIX Neurocrine
$122.17 /

-1.95 (-1.57%)

MRNA Moderna
$153.48 /

+5.94 (+4.03%)

JAZZ Jazz Pharmaceuticals
$145.16 /

+0.25 (+0.17%)

HZNP Horizon Therapeutics
$73.43 /

+0.53 (+0.73%)

GILD Gilead
$80.11 /

+0.62 (+0.78%)

BMRN BioMarin
$83.47 /

-1.38 (-1.63%)

BIIB Biogen
$281.18 /

+0.6 (+0.21%)

ARVN Arvinas
$47.20 /

-1.88 (-3.83%)

ARGX Argenx
$366.40 /

-9.73 (-2.59%)

AMGN Amgen
$266.25 /

+0.39 (+0.15%)

ARGX Argenx
$366.40 /

-9.73 (-2.59%)

10/28/22 H.C. Wainwright
Argenx price target raised to $440 from $425 at H.C. Wainwright
10/27/22 Piper Sandler
Piper Sandler remains a buyer of Argenx after Q3 beat
10/21/22 Evercore ISI
Argenx upgraded to Outperform from In Line at Evercore ISI
10/18/22 Wells Fargo
Argenx price target raised to $469 from $461 at Wells Fargo
BMRN BioMarin
$83.47 /

-1.38 (-1.63%)

10/31/22 Oppenheimer
BioMarin upgraded to Outperform from Perform at Oppenheimer
10/26/22 Piper Sandler
Handwringing over BioMarin's Roctavian misplaced, says Piper Sandler
10/24/22 JPMorgan
BioMarin price target lowered to $112 from $140 at JPMorgan
10/13/22 RBC Capital
BioMarin price target raised to $95 from $90 at RBC Capital
NBIX Neurocrine
$122.17 /

-1.95 (-1.57%)

11/02/22 BMO Capital
Neurocrine price target raised to $101 from $78 at BMO Capital
11/02/22 Wells Fargo
Neurocrine price target raised to $120 from $110 at Wells Fargo
11/02/22 RBC Capital
Neurocrine price target raised to $117 from $101 at RBC Capital
11/02/22 Cantor Fitzgerald
Neurocrine price target raised to $132 from $127 at Cantor Fitzgerald
JAZZ Jazz Pharmaceuticals
$145.16 /

+0.25 (+0.17%)

11/01/22 H.C. Wainwright
H.C. Wainwright downgrades Zymeworks on Jazz opt-out possibility
10/24/22 Stifel
Zymeworks price target lowered to $18 from $21 at Stifel
10/14/22 Guggenheim
Axsome Therapeutics price target raised to $72 from $64 at Guggenheim
08/05/22 H.C. Wainwright
Jazz Pharmaceuticals price target lowered to $204 from $210 at H.C. Wainwright
HZNP Horizon Therapeutics
$73.43 /

+0.53 (+0.73%)

11/01/22 H.C. Wainwright
Horizon Therapeutics initiated with a Neutral at H.C. Wainwright
10/25/22 Piper Sandler
Horizon Therapeutics price target lowered to $88 from $90 at Piper Sandler
08/18/22 BofA
Horizon Therapeutics and Spirit AeroSystems removed from US 1 List at BOFA
08/04/22 BMO Capital
Horizon Therapeutics price target lowered to $117 from $145 at BMO Capital
ARVN Arvinas
$47.20 /

-1.88 (-3.83%)

10/25/22 Capital One
Arvinas initiated with an Overweight at Capital One
09/09/22 Barclays
Arvinas initiated with an Overweight at Barclays
08/19/22 Piper Sandler
Arvinas should be bought on recent weakness, says Piper Sandler
08/18/22 Citi
Arvinas price target lowered to $88 from $103 at Citi
GILD Gilead
$80.11 /

+0.62 (+0.78%)

11/01/22 Guggenheim
AnaptysBio upgraded to Buy at Guggenheim on checkpoint agonist opportunity
10/31/22 Maxim
Gilead price target raised to $92 from $84 at Maxim
10/31/22 Barclays
Gilead upgraded to Equal Weight from Underweight at Barclays
10/28/22 BMO Capital
Gilead price target raised to $72 from $63 at BMO Capital
AMGN Amgen
$266.25 /

+0.39 (+0.15%)

11/04/22 Piper Sandler
Amgen price target raised to $278 from $265 at Piper Sandler
10/31/22 Barclays
Amgen downgraded to Underweight from Equal Weight at Barclays
10/20/22 Oppenheimer
Revolution Medicines initiated with an Outperform at Oppenheimer
10/12/22 Barclays
Amgen price target lowered to $234 from $236 at Barclays
BIIB Biogen
$281.18 /

+0.6 (+0.21%)

11/01/22 Mizuho
Biogen price target raised to $325 from $270 at Mizuho
10/26/22 Goldman Sachs
Biogen upgraded to Buy at Goldman Sachs on Alzheimer's opportunity
10/26/22 Goldman Sachs
Biogen upgraded to Buy from Neutral at Goldman Sachs
10/26/22 Morgan Stanley
Biogen price target raised to $325 from $321 at Morgan Stanley
MRNA Moderna
$153.48 /

+5.94 (+4.03%)

10/25/22 Morgan Stanley
Morgan Stanley expects strong results from Moderna's phase 2 trial in melanoma
10/24/22 JPMorgan
Moderna price target lowered to $122 from $165 at JPMorgan
10/21/22 SVB Securities
Moderna upgraded to Market Perform from Underperform at SVB Securities
10/21/22 SVB Securities
Moderna upgraded to Market Perform from Underperform at SVB Securities
NBIX Neurocrine
$122.17 /

-1.95 (-1.57%)

MRNA Moderna
$153.48 /

+5.94 (+4.03%)

JAZZ Jazz Pharmaceuticals
$145.16 /

+0.25 (+0.17%)

HZNP Horizon Therapeutics
$73.43 /

+0.53 (+0.73%)

GILD Gilead
$80.11 /

+0.62 (+0.78%)

BMRN BioMarin
$83.47 /

-1.38 (-1.63%)

BIIB Biogen
$281.18 /

+0.6 (+0.21%)

ARVN Arvinas
$47.20 /

-1.88 (-3.83%)

ARGX Argenx
$366.40 /

-9.73 (-2.59%)

AMGN Amgen
$266.25 /

+0.39 (+0.15%)

  • 24
    Mar
MRNA Moderna
$153.48 /

+5.94 (+4.03%)

HZNP Horizon Therapeutics
$73.43 /

+0.53 (+0.73%)

BIIB Biogen
$281.18 /

+0.6 (+0.21%)

AMGN Amgen
$266.25 /

+0.39 (+0.15%)

NBIX Neurocrine
$122.17 /

-1.95 (-1.57%)

MRNA Moderna
$153.48 /

+5.94 (+4.03%)

JAZZ Jazz Pharmaceuticals
$145.16 /

+0.25 (+0.17%)

HZNP Horizon Therapeutics
$73.43 /

+0.53 (+0.73%)

GILD Gilead
$80.11 /

+0.62 (+0.78%)

BMRN BioMarin
$83.47 /

-1.38 (-1.63%)

BIIB Biogen
$281.18 /

+0.6 (+0.21%)

ARVN Arvinas
$47.20 /

-1.88 (-3.83%)

AMGN Amgen
$266.25 /

+0.39 (+0.15%)

MRNA Moderna
$153.48 /

+5.94 (+4.03%)

GILD Gilead
$80.11 /

+0.62 (+0.78%)

BIIB Biogen
$281.18 /

+0.6 (+0.21%)

AMGN Amgen
$266.25 /

+0.39 (+0.15%)

Hot Stocks
Neurocrine presents data on Ingrezza capsule performance » 09:05
11/03/22
11/03
09:05
11/03/22
09:05
NBIX

Neurocrine

$122.01 /

+2.71 (+2.27%)

Neurocrine will present…

Neurocrine will present data from a study on Ingezza capsules evaluating in vitro dissolution performance of whole intact or crushed capsule contents in 40 mg and 80 mg strength. The data demonstrated that crushing the capsule contents of Ingrezza did not impact the dissolution performance in vitro. Additionally, very rapid and complete drug release was observed in all samples, independent of capsule strength or preparation. Neurocrine Biosciences will also present data on the long-term use of valbenazine for tardive dyskinesia in elderly patients .

ShowHide Related Items >><<
NBIX Neurocrine
$122.01 /

+2.71 (+2.27%)

NBIX Neurocrine
$122.01 /

+2.71 (+2.27%)

11/02/22 BMO Capital
Neurocrine price target raised to $101 from $78 at BMO Capital
11/02/22 Wells Fargo
Neurocrine price target raised to $120 from $110 at Wells Fargo
11/02/22 RBC Capital
Neurocrine price target raised to $117 from $101 at RBC Capital
11/02/22 Cantor Fitzgerald
Neurocrine price target raised to $132 from $127 at Cantor Fitzgerald
NBIX Neurocrine
$122.01 /

+2.71 (+2.27%)

NBIX Neurocrine
$122.01 /

+2.71 (+2.27%)

Hot Stocks
Neurocrine's valbenazine shows additional Phase 3 efficacy results » 08:35
11/03/22
11/03
08:35
11/03/22
08:35
NBIX

Neurocrine

$122.01 /

+2.71 (+2.27%)

Neurocrine reported…

Neurocrine reported additional results from the Phase 3 KINECT-HD study investigating valbenazine for the treatment of chorea associated with Huntington Disease. In December 2021, Neurocrine previously reported that once-daily administration of valbenazine was well tolerated with a statistically significant improvement in chorea associated with HD compared with placebo, along with substantial global improvement. The additional data includes an exploratory analysis of valbenazine effects over time, dosages at the end of the study, and detailed information about treatment-emergent adverse events and safety parameters. The KINECT-HD study met its primary endpoint of change in chorea severity. Improvement in the TMC score was significantly greater with valbenazine versus placebo. The secondary endpoints also significantly favored valbenazine treatment. Treatment emergent adverse events, including somnolence, fatigue, fall, and akathisia, were mild to moderate and consistent with the known safety profile of valbenazine. No suicidal behavior or worsening of suicidal ideation was observed in the valbenazine-treated subjects in this study. Enrollment continues in the KINECT-HD2 open-label study to evaluate the long-term safety and tolerability of valbenazine for the treatment of chorea in Huntington Disease.

ShowHide Related Items >><<
NBIX Neurocrine
$122.01 /

+2.71 (+2.27%)

NBIX Neurocrine
$122.01 /

+2.71 (+2.27%)

11/02/22 BMO Capital
Neurocrine price target raised to $101 from $78 at BMO Capital
11/02/22 Wells Fargo
Neurocrine price target raised to $120 from $110 at Wells Fargo
11/02/22 RBC Capital
Neurocrine price target raised to $117 from $101 at RBC Capital
11/02/22 Cantor Fitzgerald
Neurocrine price target raised to $132 from $127 at Cantor Fitzgerald
NBIX Neurocrine
$122.01 /

+2.71 (+2.27%)

NBIX Neurocrine
$122.01 /

+2.71 (+2.27%)

Recommendations
Neurocrine price target raised to $101 from $78 at BMO Capital » 08:34
11/02/22
11/02
08:34
11/02/22
08:34
NBIX

Neurocrine

$119.32 /

+4.125 (+3.58%)

BMO Capital analyst Evan…

BMO Capital analyst Evan Seigerman raised the firm's price target on Neurocrine to $101 from $78 after its Q3 earnings beat but keeps an Underperform rating on the shares. While he fully appreciates investor preference for SMid-cap Biotech names that generate revenue and profits, he remains concerned that the next billion in Ingrezza sales will be "much more expensive" and pressure margins, the analyst tells investors in a research note. Seigerman adds that he is "not comfortable" with the management's "wait-and-see approach" to the IRA.

ShowHide Related Items >><<
NBIX Neurocrine
$119.32 /

+4.125 (+3.58%)

NBIX Neurocrine
$119.32 /

+4.125 (+3.58%)

11/02/22 Wells Fargo
Neurocrine price target raised to $120 from $110 at Wells Fargo
11/02/22 RBC Capital
Neurocrine price target raised to $117 from $101 at RBC Capital
11/02/22 Cantor Fitzgerald
Neurocrine price target raised to $132 from $127 at Cantor Fitzgerald
11/02/22 Baird
Neurocrine price target raised to $150 from $125 at Baird
NBIX Neurocrine
$119.32 /

+4.125 (+3.58%)

NBIX Neurocrine
$119.32 /

+4.125 (+3.58%)

Recommendations
Neurocrine price target raised to $120 from $110 at Wells Fargo » 07:24
11/02/22
11/02
07:24
11/02/22
07:24
NBIX

Neurocrine

$119.32 /

+4.125 (+3.58%)

Wells Fargo analyst Mohit…

Wells Fargo analyst Mohit Bansal raised the firm's price target on Neurocrine to $120 from $110 and keeps an Equal Weight rating on the shares. The top-line beat and raise driven by Ingrezza in Q3 confirms the strength of the TD opportunity for Ingrezza, and the company's efforts to drive greater diagnosis rates and VMAT2 utilization, the analyst notes. As such, he raised his Ingrezza TD peak sales estimate from $2.8B to $3.1B in 2032, partially offset by an increase in OpEx to support the growing business.

ShowHide Related Items >><<
NBIX Neurocrine
$119.32 /

+4.125 (+3.58%)

NBIX Neurocrine
$119.32 /

+4.125 (+3.58%)

11/02/22 RBC Capital
Neurocrine price target raised to $117 from $101 at RBC Capital
11/02/22 Cantor Fitzgerald
Neurocrine price target raised to $132 from $127 at Cantor Fitzgerald
11/02/22 Baird
Neurocrine price target raised to $150 from $125 at Baird
11/02/22 Piper Sandler
Neurocrine price target raised to $103 from $91 at Piper Sandler
NBIX Neurocrine
$119.32 /

+4.125 (+3.58%)

NBIX Neurocrine
$119.32 /

+4.125 (+3.58%)

Recommendations
Neurocrine price target raised to $117 from $101 at RBC Capital » 07:15
11/02/22
11/02
07:15
11/02/22
07:15
NBIX

Neurocrine

$119.32 /

+4.125 (+3.58%)

RBC Capital analyst Brian…

RBC Capital analyst Brian Abrahams raised the firm's price target on Neurocrine to $117 from $101 and keeps a Sector Perform rating on the shares. The company reported a a clean beat on demand growth, and Ingrezza's commercial traction seems more sustainable than Street estimates reflect, the analyst tells investors in a research note. Abrahams adds however that while Neurocrine's growth story has "played well in this environment", he prefers to have greater visibility on its next drivers before turning more constructive.

ShowHide Related Items >><<
NBIX Neurocrine
$119.32 /

+4.125 (+3.58%)

NBIX Neurocrine
$119.32 /

+4.125 (+3.58%)

11/02/22 Cantor Fitzgerald
Neurocrine price target raised to $132 from $127 at Cantor Fitzgerald
11/02/22 Baird
Neurocrine price target raised to $150 from $125 at Baird
11/02/22 Piper Sandler
Neurocrine price target raised to $103 from $91 at Piper Sandler
10/24/22 Citi
Neurocrine price target raised to $128 from $114 at Citi
NBIX Neurocrine
$119.32 /

+4.125 (+3.58%)

NBIX Neurocrine
$119.32 /

+4.125 (+3.58%)

Recommendations
Neurocrine price target raised to $132 from $127 at Cantor Fitzgerald » 06:50
11/02/22
11/02
06:50
11/02/22
06:50
NBIX

Neurocrine

$119.32 /

+4.125 (+3.58%)

Cantor Fitzgerald analyst…

Cantor Fitzgerald analyst Charles Duncan raised the firm's price target on Neurocrine to $132 from $127 and keeps an Overweight rating on the shares. Neurocrine Biosciences reported Q3 INGREZZA net sales of $376M, well above the firm's estimates, and cash/equivalents of ~$1.2B, Duncan tells investors in a research note. The analyst remains bullish on additional long-term upside to INGREZZA sales with expansion into the LTC segment, as well as a potential approval in Huntington's disease chorea in 2023.

ShowHide Related Items >><<
NBIX Neurocrine
$119.32 /

+4.125 (+3.58%)

NBIX Neurocrine
$119.32 /

+4.125 (+3.58%)

11/02/22 Baird
Neurocrine price target raised to $150 from $125 at Baird
11/02/22 Piper Sandler
Neurocrine price target raised to $103 from $91 at Piper Sandler
10/24/22 Citi
Neurocrine price target raised to $128 from $114 at Citi
10/20/22 Mizuho
Neurocrine price target raised to $105 from $98 at Mizuho
NBIX Neurocrine
$119.32 /

+4.125 (+3.58%)

NBIX Neurocrine
$119.32 /

+4.125 (+3.58%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.